Maintenance treatment for schizophrenia with quetiapine

Peter F. Buckley

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

With the majority of current information being derived from short-term clinical trials, the impact of atypical antipsychotics during maintenance treatment of schizophrenia is of considerable interest, although only limited data are available at present. The present report is an analysis of data that are available up to 156 weeks after the start of an open-label extension (OLE) phase of three, double-blind randomized trials in quetiapine-treated patients who responded to an initial 6-week treatment period. The mean daily quetiapine dose (range 150-750mg) was 439.5 mg for patients included in the brief psychiatric rating scale (BPRS) and 438.5 mg for patients included in the clinical global impression (CGI) analyses. The initial mean acute phase BPRS total score (40.67; n = 258) and CGI severity of illness score (4.81; n = 259) were reduced at the start of the OLE to 13.94 and 3.00, respectively. After 156 weeks, endpoint scores were 9.04 for BPRS and 2.43 for CGI severity of illness. Although limited by patient attrition, these OLE data suggest that an initial beneficial response with quetiapine treatment can be maintained over a long-term period.

Original languageEnglish (US)
Pages (from-to)121-124
Number of pages4
JournalHuman Psychopharmacology
Volume19
Issue number2
DOIs
StatePublished - Mar 1 2004

Fingerprint

Brief Psychiatric Rating Scale
Schizophrenia
Therapeutics
Antipsychotic Agents
Clinical Trials
Quetiapine Fumarate

Keywords

  • Atypical antipsychotics
  • Maintenance
  • Quetiapine
  • Schizophrenia

ASJC Scopus subject areas

  • Neurology
  • Clinical Neurology
  • Psychiatry and Mental health
  • Pharmacology (medical)

Cite this

Maintenance treatment for schizophrenia with quetiapine. / Buckley, Peter F.

In: Human Psychopharmacology, Vol. 19, No. 2, 01.03.2004, p. 121-124.

Research output: Contribution to journalArticle

Buckley, Peter F. / Maintenance treatment for schizophrenia with quetiapine. In: Human Psychopharmacology. 2004 ; Vol. 19, No. 2. pp. 121-124.
@article{78e98c06fe8d43f3b8c83eb94abf2cbe,
title = "Maintenance treatment for schizophrenia with quetiapine",
abstract = "With the majority of current information being derived from short-term clinical trials, the impact of atypical antipsychotics during maintenance treatment of schizophrenia is of considerable interest, although only limited data are available at present. The present report is an analysis of data that are available up to 156 weeks after the start of an open-label extension (OLE) phase of three, double-blind randomized trials in quetiapine-treated patients who responded to an initial 6-week treatment period. The mean daily quetiapine dose (range 150-750mg) was 439.5 mg for patients included in the brief psychiatric rating scale (BPRS) and 438.5 mg for patients included in the clinical global impression (CGI) analyses. The initial mean acute phase BPRS total score (40.67; n = 258) and CGI severity of illness score (4.81; n = 259) were reduced at the start of the OLE to 13.94 and 3.00, respectively. After 156 weeks, endpoint scores were 9.04 for BPRS and 2.43 for CGI severity of illness. Although limited by patient attrition, these OLE data suggest that an initial beneficial response with quetiapine treatment can be maintained over a long-term period.",
keywords = "Atypical antipsychotics, Maintenance, Quetiapine, Schizophrenia",
author = "Buckley, {Peter F.}",
year = "2004",
month = "3",
day = "1",
doi = "10.1002/hup.573",
language = "English (US)",
volume = "19",
pages = "121--124",
journal = "Human Psychopharmacology",
issn = "0885-6222",
publisher = "John Wiley and Sons Ltd",
number = "2",

}

TY - JOUR

T1 - Maintenance treatment for schizophrenia with quetiapine

AU - Buckley, Peter F.

PY - 2004/3/1

Y1 - 2004/3/1

N2 - With the majority of current information being derived from short-term clinical trials, the impact of atypical antipsychotics during maintenance treatment of schizophrenia is of considerable interest, although only limited data are available at present. The present report is an analysis of data that are available up to 156 weeks after the start of an open-label extension (OLE) phase of three, double-blind randomized trials in quetiapine-treated patients who responded to an initial 6-week treatment period. The mean daily quetiapine dose (range 150-750mg) was 439.5 mg for patients included in the brief psychiatric rating scale (BPRS) and 438.5 mg for patients included in the clinical global impression (CGI) analyses. The initial mean acute phase BPRS total score (40.67; n = 258) and CGI severity of illness score (4.81; n = 259) were reduced at the start of the OLE to 13.94 and 3.00, respectively. After 156 weeks, endpoint scores were 9.04 for BPRS and 2.43 for CGI severity of illness. Although limited by patient attrition, these OLE data suggest that an initial beneficial response with quetiapine treatment can be maintained over a long-term period.

AB - With the majority of current information being derived from short-term clinical trials, the impact of atypical antipsychotics during maintenance treatment of schizophrenia is of considerable interest, although only limited data are available at present. The present report is an analysis of data that are available up to 156 weeks after the start of an open-label extension (OLE) phase of three, double-blind randomized trials in quetiapine-treated patients who responded to an initial 6-week treatment period. The mean daily quetiapine dose (range 150-750mg) was 439.5 mg for patients included in the brief psychiatric rating scale (BPRS) and 438.5 mg for patients included in the clinical global impression (CGI) analyses. The initial mean acute phase BPRS total score (40.67; n = 258) and CGI severity of illness score (4.81; n = 259) were reduced at the start of the OLE to 13.94 and 3.00, respectively. After 156 weeks, endpoint scores were 9.04 for BPRS and 2.43 for CGI severity of illness. Although limited by patient attrition, these OLE data suggest that an initial beneficial response with quetiapine treatment can be maintained over a long-term period.

KW - Atypical antipsychotics

KW - Maintenance

KW - Quetiapine

KW - Schizophrenia

UR - http://www.scopus.com/inward/record.url?scp=1542516233&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=1542516233&partnerID=8YFLogxK

U2 - 10.1002/hup.573

DO - 10.1002/hup.573

M3 - Article

C2 - 14994322

AN - SCOPUS:1542516233

VL - 19

SP - 121

EP - 124

JO - Human Psychopharmacology

JF - Human Psychopharmacology

SN - 0885-6222

IS - 2

ER -